ClinicalTrials.gg
CompletedNCT00679939Updated Apr 18, 2018Results posted

Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health

A Phase 4 interventional study of Rosiglitazone and Metformin in Diabetes Mellitus, Type 2, sponsored by GlaxoSmithKline. Completed at 42 sites in 8 countries. Open to female participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-04-18.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
226
Allocation
Randomized
Ages
55 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Rosiglitazone · Diabetes Mellitus, Type 2.

Enrollment
22nd of 51
226 · median 149
Started
2008
with 1 other
Phase 4
21 of 52
none open now
Registered
47th of 52
by date
Lead sponsor
22 of 52
GlaxoSmithKline

Among the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2, this one is the 22nd largest by enrollment of the 51 interventional ones that give a count, is one of 2 that started in 2008, is one of 21 in phase 4, and was the 47th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About rosiglitazone

Rosiglitazone: first FDA approval 1999 (AVANDIA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 55 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The purpose of this study is to determine the effects of rosiglitazone on the bone in postmenopausal women with type 2 diabetes mellitus

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Type 2 diabetes mellitus
  • bone
  • x-ray absorptiometry
  • bone biomarkers
  • dual-energy
  • bone mineral density
04

Who can participate

Ages eligible
55 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female, >55 to \<80 years
  • >5 years menopausal
  • Type 2 Diabetes Mellitus (T2DM) diagnosis according to American Diabetes Association (ADA), American Association of Clinical Endocrinologists (AACE), Canadian Diabetes Association (CDA), World Health Organization/International Diabetes Federation (WHO/IDF)
  • Drug-naïve ( \< or = 9.0%); OR Prior monotherapy, submaximal doses of metformin (\< or = 1000mg Metformin), sulfonylureas (\< or = 5mg Glyburide, \< or = 10mg Glipizide or \< or = 8mg glimepiride) or full dose Januvia (100mg) (HbA1c \< or = 8.5%); OR Prior monotherapy, > submaximal doses of metformin (>1000mg) or sulfonylureas (>5mg Glyburide, >10mg Glipizide or >8mg glimepiride) (HbA1c \< or = 7.0%)
  • Weighs \<300 lbs (136.4 kg)
  • Two or more vertebra (L1-L4) suitable for BMD measurement by dual x-ray absorptiometry (DXA)
  • Absolute BMD value consistent with T-score >-2.5 at femoral neck, lumbar spine and total hip

Exclusion criteria

Exclusion Criteria:

  • Type 1 Diabetes Mellitus (T1DM) or history of diabetic ketoacidosis (DKA)
  • Renal or hepatic disease ()
  • Hepatocellular reaction, severe edema, or medically serious fluid event associated with thiazolidinedione (TZD)
  • Recent (\<6mos) history or clinical intervention for angina or myocardial infarction or is taking nitrates
  • Any stage of heart failure, i.e. (NYHA) class I-IV
  • Systolic BP >160mmHg or diastolic BP >90mmHg while on antihypertensive
  • to TZDs, biguanides
  • Prior treatment with two or more oral anti-diabetic (OAD) agents
  • Bilateral hip replacements
  • Concurrent diseases affecting bone metabolism
  • Active malabsorption syndrome
  • Serum calcium outside the central lab reference range
  • Thyroid replacement therapy, serum thyroid stimulating hormone (TSH) must be within range
  • Vitamin D deficiency
  • Previous treatment with: strontium, intravenous (IV) bisphosphonate, fluoride, hormones, calcineurin inhibitors or methotrexate
  • Chronic systemic [e.g. glucocorticoid, mineralocorticoid] treatment of no more than two intra-articular injections within the past year or use of oral parenteral, or long-term, high-dose inhaled corticosteroids
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
226 participants (actual)

Study arms

  • Active comparator
    Arm 1 Treatment A

    rosiglitazone up to 8mg/day

    Drug: Rosiglitazone

  • Active comparator
    Arm 2 Treatment B

    metformin up to 2000mg/day

    Drug: Metformin

Interventions

06

What researchers measure

Primary outcomes

  1. Adjusted Percent Change From Baseline in Femoral Neck (FN) Bone Mineral Density (BMD) Via Dual-energy X-ray Absorptiometry (DXA) at Week 52

    FN BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Bone mineral density is calculated as the mineral content of a bone divided by the area of the bone. DXA is the principal technique used for measuring BMD. Percent change from Baseline at Week 52 was calculated as (BMD at Week 52 minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Change in FN BMD at Week 52 was only analyzed within the Rosiglitazone arm.

    Time frame: Baseline and Week 52

  2. Adjusted Percent Change From Baseline in Femoral Neck (FN) Bone Mineral Density (BMD) Via Dual-energy X-ray Absorptiometry (DXA) at Week 76+10 Days

    FN BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Bone mineral density is calculated as the mineral content of a bone divided by the area of the bone. DXA is the principal technique used for measuring BMD. Percent change from Baseline at Week 76+10 days was calculated as (BMD at Week 76+10 days minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.

    Time frame: Baseline and Week 76+10 days

  3. Adjusted Percent Change in Femoral Neck (FN) Bone Mineral Density (BMD) Via Dual-energy X-ray Absorptiometry (DXA) From Week 52 +10 Days to Week 76+10 Days

    FN BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Bone mineral density is calculated as the mineral content of a bone divided by the area of the bone. DXA is the principal technique used for measuring BMD. Percent change from Week 52+10 days to Week 76+10 days was calculated as (BMD at Week 76+10 days minus BMD at Week 52+10 days)/BMD at Week 52+10 days x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.

    Time frame: Week 52+10 days and Week 76+10 days

Secondary outcomes

  1. Adjusted Percent Change From Baseline in Femoral Neck, Total Hip, Trochanter, and Lumbar Spine BMD Via DXA at Week 52

    BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Percent change from Baseline at Week 52 was calculated as (BMD at Week 52 minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.

    Time frame: Baseline and Week 52

  2. Adjusted Percent Change in Femoral Neck, Total Hip, Trochanter, and Lumbar Spine BMD Via DXA From Week 52+10 Days to Week 76 + 10 Days

    BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Percent change from Week 52 + 10 days toat Week 76 + 10 days was calculated as (BMD at Week 76 + 10 days minus BMD at Week 52 + 10 days)/BMD at Week 52 + 10 days x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.

    Time frame: Week 52 + 10 days and Week 76 + 10 days

  3. Adjusted Percent Change in Femoral Neck, Total Hip, Trochanter, and Lumbar Spine BMD Via DXA From Week 52+30 Days to Week 76 + 30 Days

    BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (BMD at Week 76 + 30 days minus BMD at Week 52 + 30 days)/BMD at Week 52 + 30 days x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.

    Time frame: Week 52 + 30 days and Week 76 + 30 days

  4. Adjusted Percent Change From Baseline in Bone Specific Alkaline Phosphatase (BSAP) and Procollagen Type 1 N-propeptide (P1NP) at Week 52 and Week 76

    BSAP and P1NP levels were measured in micrograms per liter (mcg/L) from blood samples. BSAP and P1NP are indicators of bone buildup or formation. GM, geometric mean; SE, standard error. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.

    Time frame: Baseline, Week 52, and Week 76

  5. Adjusted Percent Change in Bone Specific Alkaline Phosphatase (BSAP) and Procollagen Type 1 N-propeptide (P1NP) From Week 52 to Week 76

    BSAP and P1NP levels were measured in micrograms per liter (mcg/L) from blood samples. BSAP and P1NP are indicators of bone buildup or formation. GM, geometric mean; SE, standard error. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.

    Time frame: Week 52 and Week 76

  6. Adjusted Percent Change From Baseline in Carboxyterminal Cross-linked Telopeptide of Type 1 Collagen (CTX) at Week 52 and Week 76

    CTX levels were measured in picograms per milliliter (pg/ml) from blood samples. CTX is an indicator of bone break down or resorption. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.

    Time frame: Baseline, Week 52, and Week 76

  7. Adjusted Percent Change in Carboxyterminal Cross-linked Telopeptide of Type 1 Collagen (CTX) From Week 52 to Week 76

    CTX levels were measured in picograms per milliliter (pg/ml) from blood samples. CTX is an indicator of bone break down or resorption. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.

    Time frame: Week 52 and Week 76

  8. Adjusted Percent Change From Baseline in 25-Hydroxyvitamin D (Vitamin D) at Week 52 and Week 76

    Vitamin D levels were measured in nanomoles per Liter (nmol/L) from blood samples. Vitamin D is required for good bone health. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.

    Time frame: Baseline, Week 52, and Week 76

  9. Adjusted Percent Change in 25-Hydroxyvitamin D (Vitamin D) From Week 52 to Week 76

    Vitamin D levels were measured in nanomoles per Liter (nmol/L) from blood samples. Vitamin D is required for good bone health. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.

    Time frame: Week 52 and Week 76

  10. Adjusted Percent Change From Baseline in Intact Parathyroid Hormone (PTH) at Week 52 and Week 76

    Intact PTH levels were measured in nanograms per Liter (ng/L) from blood samples. Intact PTH is the amount of PTH circulating in the blood and influences bone health. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.

    Time frame: Baseline, Week 52, and Week 76

  11. Adjusted Percent Change in Intact Parathyroid Hormone (PTH) From Week 52 to Week 76

    Intact PTH levels were measured in nanograms per Liter (ng/L) from blood samples. Intact PTH is the amount of PTH circulating in the blood and influences bone health. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.

    Time frame: Week 52 and Week 76

  12. Percent Change From Baseline in Serum Estradiol at Week 52 and Week 76

    Serum estradiol levels were measured in picomoles per Liter (pmol/L) from blood samples. Estradiol is one form of the female sex hormone estrogen and influences bone health. Percent change from baseline was based on log-transformed data.

    Time frame: Baseline, Week 52, and Week 76

  13. Percent Change in Serum Estradiol From Week 52 to Week 76

    Serum estradiol levels were measured in picomoles per Liter (pmol/L) from blood samples. Estradiol is one form of the female sex hormone estrogen and influences bone health. Percent change from baseline was based on log-transformed data.

    Time frame: Week 52 and Week 76

  14. Percent Change From Baseline in Total Testosterone at Week 52 and Week 76

    Total testosterone levels were measured in nanomoles per Liter (nmol/L) from blood samples. Testosterone is a male sex hormone and influences bone health; total testosterone is the entire amount circulating in blood. Percent change from baseline was based on log-transformed data.

    Time frame: Baseline, Week 52, and Week 76

  15. Percent Change in Total Testosterone From Week 52 to Week 76

    Total testosterone levels were measured in nanomoles per Liter (nmol/L) from blood samples. Testosterone is a male sex hormone and influences bone health; total testosterone is the entire amount circulating in blood. Percent change from baseline was based on log-transformed data.

    Time frame: Week 52 and Week 76

  16. Percent Change From Baseline in Free Testosterone at Week 52 and Week 76

    Free testosterone levels were measured as a percentage of total testosterone from blood samples. Free testosterone is the amount of testosterone available to the body for use. Percent change from baseline was based on log-transformed data.

    Time frame: Baseline, Week 52, and Week 76

  17. Percent Change in Free Testosterone From Week 52 to Week 76

    Free testosterone levels were measured as a percentage of total testosterone from blood samples. Free testosterone is the amount of testosterone available to the body for use. Percent change from baseline was based on log-transformed data.

    Time frame: Week 52 and Week 76

  18. Percent Change From Baseline in Sex Hormone Binding Globulin (SHBG) at Week 52 and Week 76

    SHBG levels were measured in nanomoles per liter (nmol/L) from blood samples. SHBG binds to estradiol and testosterone and influences the amount of estradiol or testosterone available to the body for use. Percent change from baseline was based on log-transformed data.

    Time frame: Baseline, Week 52, and Week 76

  19. Percent Change in Sex Hormone Binding Globulin (SHBG) From Week 52 to Week 76

    SHBG levels were measured in nanomoles per liter (nmol/L) from blood samples. SHBG binds to estradiol and testosterone and influences the amount of estradiol or testosterone available to the body for use. Percent change from baseline was based on log-transformed data.

    Time frame: Week 52 and Week 76

Other outcomes

  1. Percent Change in Percentage of Free Estradiol From Week 52 to Week 76

    Free estradiol levels were measured as a percentage of serum estrogen from blood samples. Free estradiol is the amount of estrogen available to the body for use. Percent change was based on log-transformed data.

    Time frame: Week 52 and Week 76

  2. Percent Change in Free Estradiol From Week 52 to Week 76

    Free estradiol levels were measured in picomoles per Liter (pmol/L) from blood samples. Free estrodial is the amount of estrogen available to the body for use. Change was based on log-transformed data.

    Time frame: Week 52 and Week 76

07

Results

Posted Mar 7, 2011

Participant flow

52-Week Double-Blind (DB) Period
Participant flow — 52-Week Double-Blind (DB) Period
MilestoneRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Started114112
Completed7785
Not completed3727
Withdrew: Withdrew consent1713
Withdrew: Adverse event1412
Withdrew: Investigator discretion50
Withdrew: Protocol violation10
Withdrew: Lost to follow-up02
24-Week Open-Label (OL) Period
Participant flow — 24-Week Open-Label (OL) Period
MilestoneRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Started7684
Completed6980
Not completed74
Withdrew: Adverse event01
Withdrew: Protocol violation11
Withdrew: Met stopping criteria31
Withdrew: Physician decision10
Withdrew: Withdrawal by subject21

Outcome measures

PrimaryAdjusted Percent Change From Baseline in Femoral Neck (FN) Bone Mineral Density (BMD) Via Dual-energy X-ray Absorptiometry (DXA) at Week 52

FN BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Bone mineral density is calculated as the mineral content of a bone divided by the area of the bone. DXA is the principal technique used for measuring BMD. Percent change from Baseline at Week 52 was calculated as (BMD at Week 52 minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Change in FN BMD at Week 52 was only analyzed within the Rosiglitazone arm.

Time frame:
Baseline and Week 52
Reported as:
Mean · percent change
Adjusted Percent Change From Baseline in Femoral Neck (FN) Bone Mineral Density (BMD) Via Dual-energy X-ray Absorptiometry (DXA) at Week 52
percent changeRosiglitazone in DB Period; Metformin in OL Period
Adjusted Percent Change From Baseline in Femoral Neck (FN) Bone Mineral Density (BMD) Via Dual-energy X-ray Absorptiometry (DXA) at Week 52-1.24 ± 0.619
PrimaryAdjusted Percent Change From Baseline in Femoral Neck (FN) Bone Mineral Density (BMD) Via Dual-energy X-ray Absorptiometry (DXA) at Week 76+10 Days

FN BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Bone mineral density is calculated as the mineral content of a bone divided by the area of the bone. DXA is the principal technique used for measuring BMD. Percent change from Baseline at Week 76+10 days was calculated as (BMD at Week 76+10 days minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Baseline and Week 76+10 days
Reported as:
Mean · percent change
Adjusted Percent Change From Baseline in Femoral Neck (FN) Bone Mineral Density (BMD) Via Dual-energy X-ray Absorptiometry (DXA) at Week 76+10 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Adjusted Percent Change From Baseline in Femoral Neck (FN) Bone Mineral Density (BMD) Via Dual-energy X-ray Absorptiometry (DXA) at Week 76+10 Days-1.91 ± 0.6240.31 ± 0.636
PrimaryAdjusted Percent Change in Femoral Neck (FN) Bone Mineral Density (BMD) Via Dual-energy X-ray Absorptiometry (DXA) From Week 52 +10 Days to Week 76+10 Days

FN BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Bone mineral density is calculated as the mineral content of a bone divided by the area of the bone. DXA is the principal technique used for measuring BMD. Percent change from Week 52+10 days to Week 76+10 days was calculated as (BMD at Week 76+10 days minus BMD at Week 52+10 days)/BMD at Week 52+10 days x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Week 52+10 days and Week 76+10 days
Reported as:
Mean · percent change
Adjusted Percent Change in Femoral Neck (FN) Bone Mineral Density (BMD) Via Dual-energy X-ray Absorptiometry (DXA) From Week 52 +10 Days to Week 76+10 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Adjusted Percent Change in Femoral Neck (FN) Bone Mineral Density (BMD) Via Dual-energy X-ray Absorptiometry (DXA) From Week 52 +10 Days to Week 76+10 Days-0.07 ± 0.589-0.02 ± 0.585
SecondaryAdjusted Percent Change From Baseline in Femoral Neck, Total Hip, Trochanter, and Lumbar Spine BMD Via DXA at Week 52

BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Percent change from Baseline at Week 52 was calculated as (BMD at Week 52 minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Baseline and Week 52
Reported as:
Mean · percent change
Adjusted Percent Change From Baseline in Femoral Neck, Total Hip, Trochanter, and Lumbar Spine BMD Via DXA at Week 52
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Femoral neck, n=52, 54-1.24 ± 0.6190.72 ± 0.659
Total hip, n=52, 54-0.77 ± 0.417-0.38 ± 0.440
Trochanter, n=52, 54-0.21 ± 0.725-0.78 ± 0.768
Lumbar spine, n=51, 53-1.21 ± 0.4730.12 ± 0.505
SecondaryAdjusted Percent Change in Femoral Neck, Total Hip, Trochanter, and Lumbar Spine BMD Via DXA From Week 52+10 Days to Week 76 + 10 Days

BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Percent change from Week 52 + 10 days toat Week 76 + 10 days was calculated as (BMD at Week 76 + 10 days minus BMD at Week 52 + 10 days)/BMD at Week 52 + 10 days x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Week 52 + 10 days and Week 76 + 10 days
Reported as:
Mean · percent change
Adjusted Percent Change in Femoral Neck, Total Hip, Trochanter, and Lumbar Spine BMD Via DXA From Week 52+10 Days to Week 76 + 10 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Femoral neck, n=56, 62-0.07 ± 0.589-0.02 ± 0.585
Total hip, n=56, 620.40 ± 0.304-0.13 ± 0.301
Trochanter, n=56, 62-0.02 ± 0.475-0.68 ± 0.469
Lumbar spine, n=55, 620.26 ± 0.4401.03 ± 0.442
SecondaryAdjusted Percent Change in Femoral Neck, Total Hip, Trochanter, and Lumbar Spine BMD Via DXA From Week 52+30 Days to Week 76 + 30 Days

BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (BMD at Week 76 + 30 days minus BMD at Week 52 + 30 days)/BMD at Week 52 + 30 days x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Week 52 + 30 days and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change in Femoral Neck, Total Hip, Trochanter, and Lumbar Spine BMD Via DXA From Week 52+30 Days to Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Femoral neck, n=64, 73-0.27 ± 0.559-0.25 ± 0.535
Total hip, n=64, 730.00 ± 0.298-0.27 ± 0.283
Trochanter, n=64, 73-0.17 ± 0.495-0.47 ± 0.470
Lumbar spine, n=65, 700.54 ± 0.4450.90 ± 0.442
SecondaryAdjusted Percent Change From Baseline in Bone Specific Alkaline Phosphatase (BSAP) and Procollagen Type 1 N-propeptide (P1NP) at Week 52 and Week 76

BSAP and P1NP levels were measured in micrograms per liter (mcg/L) from blood samples. BSAP and P1NP are indicators of bone buildup or formation. GM, geometric mean; SE, standard error. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Baseline, Week 52, and Week 76
Reported as:
Number · percent change
Adjusted Percent Change From Baseline in Bone Specific Alkaline Phosphatase (BSAP) and Procollagen Type 1 N-propeptide (P1NP) at Week 52 and Week 76
percent changeRosiglitazoneMetformin
Week 52, GM - SE, BSAP, n=78, 84-15.2-29.7
Week 52, GM, BSAP, n=78, 84-12.3-27.3
Week 52, GM + SE, BSAP, n=78, 84-9.3-24.8
Week 76, GM - SE, BSAP, n=64, 77-18.7-26.7
Week 76, GM, BSAP, n=64, 77-15.9-24.3
Week 76, GM + SE, BSAP, n=64, 77-12.9-21.8
Week 52, GM - SE, P1NP, n=76, 835.0-16.5
Week 52, GM, P1NP, n=76, 839.0-13.3
Week 52, GM + SE, P1NP, n=76, 8313.3-9.9
Week 76 GM - SE, P1NP, n=63, 75-11.2-14.5
Week 76, GM, P1NP, n=63, 75-6.9-10.5
Week 76, GM + SE, P1NP, n=63, 75-2.4-6.4
SecondaryAdjusted Percent Change in Bone Specific Alkaline Phosphatase (BSAP) and Procollagen Type 1 N-propeptide (P1NP) From Week 52 to Week 76

BSAP and P1NP levels were measured in micrograms per liter (mcg/L) from blood samples. BSAP and P1NP are indicators of bone buildup or formation. GM, geometric mean; SE, standard error. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Week 52 and Week 76
Reported as:
Number · percent change
Adjusted Percent Change in Bone Specific Alkaline Phosphatase (BSAP) and Procollagen Type 1 N-propeptide (P1NP) From Week 52 to Week 76
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
GM - SE, BSAP, n=64, 76-5.64.3
GM, BSAP, n=64, 76-2.08.0
GM + SE, BSAP, n=64, 761.811.8
GM - SE, P1NP, n=63, 76-15.83.2
GM, P1NP, n=63, 76-12.47.0
GM + SE, P1NP, n=63, 76-9.011.0
SecondaryAdjusted Percent Change From Baseline in Carboxyterminal Cross-linked Telopeptide of Type 1 Collagen (CTX) at Week 52 and Week 76

CTX levels were measured in picograms per milliliter (pg/ml) from blood samples. CTX is an indicator of bone break down or resorption. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Baseline, Week 52, and Week 76
Reported as:
Number · percent change
Adjusted Percent Change From Baseline in Carboxyterminal Cross-linked Telopeptide of Type 1 Collagen (CTX) at Week 52 and Week 76
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Week 52, GM - SE, n=77, 8411.3-7.8
Week 52, GM, n=77, 8418.1-2.3
Week 52, GM + SE, n=77, 8425.43.7
Week 76, GM - SE, n=63, 77-19.5-4.5
Week 76, GM, n=63, 77-13.12.6
Week 76, GM + SE, n=63, 77-6.110.3
SecondaryAdjusted Percent Change in Carboxyterminal Cross-linked Telopeptide of Type 1 Collagen (CTX) From Week 52 to Week 76

CTX levels were measured in picograms per milliliter (pg/ml) from blood samples. CTX is an indicator of bone break down or resorption. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Week 52 and Week 76
Reported as:
Number · percent change
Adjusted Percent Change in Carboxyterminal Cross-linked Telopeptide of Type 1 Collagen (CTX) From Week 52 to Week 76
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
GM - SE-31.22.2
GM-26.78.4
GM + SE-21.914.9
SecondaryAdjusted Percent Change From Baseline in 25-Hydroxyvitamin D (Vitamin D) at Week 52 and Week 76

Vitamin D levels were measured in nanomoles per Liter (nmol/L) from blood samples. Vitamin D is required for good bone health. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Baseline, Week 52, and Week 76
Reported as:
Number · percent change
Adjusted Percent Change From Baseline in 25-Hydroxyvitamin D (Vitamin D) at Week 52 and Week 76
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Week 52, GM - SE, n=61, 65-27.9-15.9
Week 52, GM, n=61, 65-24.7-12.2
Week 52, GM + SE, n=61, 65-21.4-8.4
Week 76, GM - SE, n=55, 58-21.3-12.5
Week 76, GM, n=55, 58-18.1-8.9
Week 76, GM + SE, n=55, 58-14.6-5.2
SecondaryAdjusted Percent Change in 25-Hydroxyvitamin D (Vitamin D) From Week 52 to Week 76

Vitamin D levels were measured in nanomoles per Liter (nmol/L) from blood samples. Vitamin D is required for good bone health. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Week 52 and Week 76
Reported as:
Number · percent change
Adjusted Percent Change in 25-Hydroxyvitamin D (Vitamin D) From Week 52 to Week 76
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
GM - SE-4.7-7.7
GM0.1-3.2
GM + SE5.11.5
SecondaryAdjusted Percent Change From Baseline in Intact Parathyroid Hormone (PTH) at Week 52 and Week 76

Intact PTH levels were measured in nanograms per Liter (ng/L) from blood samples. Intact PTH is the amount of PTH circulating in the blood and influences bone health. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Baseline, Week 52, and Week 76
Reported as:
Number · percent change
Adjusted Percent Change From Baseline in Intact Parathyroid Hormone (PTH) at Week 52 and Week 76
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Week 52, GM - SE, n=64, 71-16.5-25.9
Week 52, GM, n=64, 71-12.0-22.0
Week 52, GM + SE, n=64, 71-7.2-17.8
Week 76, GM - SE, n=56, 64-28.8-26.2
Week 76, GM, n=56, 64-23.1-20.8
Week 76, GM + SE, n=56, 64-17.0-15.0
SecondaryAdjusted Percent Change in Intact Parathyroid Hormone (PTH) From Week 52 to Week 76

Intact PTH levels were measured in nanograms per Liter (ng/L) from blood samples. Intact PTH is the amount of PTH circulating in the blood and influences bone health. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Week 52 and Week 76
Reported as:
Number · percent change
Adjusted Percent Change in Intact Parathyroid Hormone (PTH) From Week 52 to Week 76
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
GM - SE-13.2-1.7
GM-7.44.3
GM + SE-1.310.7
SecondaryPercent Change From Baseline in Serum Estradiol at Week 52 and Week 76

Serum estradiol levels were measured in picomoles per Liter (pmol/L) from blood samples. Estradiol is one form of the female sex hormone estrogen and influences bone health. Percent change from baseline was based on log-transformed data.

Time frame:
Baseline, Week 52, and Week 76
Reported as:
Number · percent change
Percent Change From Baseline in Serum Estradiol at Week 52 and Week 76
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Week 52, GM - SE, n=74, 82-17.0838-31.4166
Week 52, GM, n=74, 82-3.453-17.280
Weel 52, GM + SE, n=74, 8212.4189-0.2292
Week 76, GM - SE, n=64, 76-16.09710.4372
Week 76, GM, n=64, 760.21521.389
Week 76, GM + SE, n=64, 7619.698746.7122
SecondaryPercent Change in Serum Estradiol From Week 52 to Week 76

Serum estradiol levels were measured in picomoles per Liter (pmol/L) from blood samples. Estradiol is one form of the female sex hormone estrogen and influences bone health. Percent change from baseline was based on log-transformed data.

Time frame:
Week 52 and Week 76
Reported as:
Number · percent change
Percent Change in Serum Estradiol From Week 52 to Week 76
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
GM - SE-15.205629.3058
GM0.51350.823
GM + SE19.144775.9217
SecondaryPercent Change From Baseline in Total Testosterone at Week 52 and Week 76

Total testosterone levels were measured in nanomoles per Liter (nmol/L) from blood samples. Testosterone is a male sex hormone and influences bone health; total testosterone is the entire amount circulating in blood. Percent change from baseline was based on log-transformed data.

Time frame:
Baseline, Week 52, and Week 76
Reported as:
Number · percent change
Percent Change From Baseline in Total Testosterone at Week 52 and Week 76
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Week 52, GM - SE, n=74, 8214.1569-5.8206
Week 52, GM, n=74, 8219.6891.044
Week 52, GM + SE, n=74, 8225.48978.4082
Week 76, GM - SE, n=64, 75-12.5441-8.2870
Week 76, GM, n=64, 75-8.156-2.932
Week 76, GM + SE, n=64, 75-3.54702.7363
SecondaryPercent Change in Total Testosterone From Week 52 to Week 76

Total testosterone levels were measured in nanomoles per Liter (nmol/L) from blood samples. Testosterone is a male sex hormone and influences bone health; total testosterone is the entire amount circulating in blood. Percent change from baseline was based on log-transformed data.

Time frame:
Week 52 and Week 76
Reported as:
Number · percent change
Percent Change in Total Testosterone From Week 52 to Week 76
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
GM - SE-29.0307-13.9923
GM-24.373-7.102
GM + SE-19.41040.3411
SecondaryPercent Change From Baseline in Free Testosterone at Week 52 and Week 76

Free testosterone levels were measured as a percentage of total testosterone from blood samples. Free testosterone is the amount of testosterone available to the body for use. Percent change from baseline was based on log-transformed data.

Time frame:
Baseline, Week 52, and Week 76
Reported as:
Number · percent change
Percent Change From Baseline in Free Testosterone at Week 52 and Week 76
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Week 52, GM - SE, n=74, 82-9.99642.5725
Week 52, GM, n=74, 82-5.9406.266
Week 52, GM + SE, n=74, 821.700610.0934
Week 76, GM - SE, n=64, 75-0.3232-1.9532
Week 76, GM, n=64, 753.6872.478
Week 76, GM + SE, n=64, 757.85937.1093
SecondaryPercent Change in Free Testosterone From Week 52 to Week 76

Free testosterone levels were measured as a percentage of total testosterone from blood samples. Free testosterone is the amount of testosterone available to the body for use. Percent change from baseline was based on log-transformed data.

Time frame:
Week 52 and Week 76
Reported as:
Number · percent change
Percent Change in Free Testosterone From Week 52 to Week 76
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
GM - SE3.1109-6.9549
GM8.993-3.537
GM + SE15.21000.0073
SecondaryPercent Change From Baseline in Sex Hormone Binding Globulin (SHBG) at Week 52 and Week 76

SHBG levels were measured in nanomoles per liter (nmol/L) from blood samples. SHBG binds to estradiol and testosterone and influences the amount of estradiol or testosterone available to the body for use. Percent change from baseline was based on log-transformed data.

Time frame:
Baseline, Week 52, and Week 76
Reported as:
Number · percent change
Percent Change From Baseline in Sex Hormone Binding Globulin (SHBG) at Week 52 and Week 76
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Week 52, GM - SE, n=74, 8333.26084.3929
Week 52, GM, n=74, 8337.5638.146
Week 52, GM + SE, n=74, 8342.004912.0349
Week 76, GM - SE, n=61, 67-0.29734.0983
Week 76, GM, n=61, 673.1379.846
Week 76, GM + SE, n=61, 676.689615.9116
SecondaryPercent Change in Sex Hormone Binding Globulin (SHBG) From Week 52 to Week 76

SHBG levels were measured in nanomoles per liter (nmol/L) from blood samples. SHBG binds to estradiol and testosterone and influences the amount of estradiol or testosterone available to the body for use. Percent change from baseline was based on log-transformed data.

Time frame:
Week 52 and Week 76
Reported as:
Number · percent change
Percent Change in Sex Hormone Binding Globulin (SHBG) From Week 52 to Week 76
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
GM - SE-27.0129-3.9036
GM-24.624-0.825
GM + SE-22.15662.3517
Other pre-specifiedPercent Change in Percentage of Free Estradiol From Week 52 to Week 76

Free estradiol levels were measured as a percentage of serum estrogen from blood samples. Free estradiol is the amount of estrogen available to the body for use. Percent change was based on log-transformed data.

Time frame:
Week 52 and Week 76
Reported as:
Number · percent change
Percent Change in Percentage of Free Estradiol From Week 52 to Week 76
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
GM - SE-7.6337-5.4666
GM-2.683-0.975
GM + SE2.53373.7301
Other pre-specifiedPercent Change in Free Estradiol From Week 52 to Week 76

Free estradiol levels were measured in picomoles per Liter (pmol/L) from blood samples. Free estrodial is the amount of estrogen available to the body for use. Change was based on log-transformed data.

Time frame:
Week 52 and Week 76
Reported as:
Number · percent change
Percent Change in Free Estradiol From Week 52 to Week 76
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
GM - SE-29.525096.1843
GM-3.239173.932
GM + SE32.8525282.4903
Post-hocAdjusted Percent Change From Baseline in Femoral Neck, Total Hip, Trochanter, and Lumbar Spine BMD Via DXA at Week 52 + 10 Days and Week 76 + 10 Days

BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Percent change from Baseline at Week 52 + 10 days or Week 76 + 10 days was calculated as (BMD at Week 52 + 10 days (or Week 76 + 10 days ) minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Baseline, Week 52 + 10 days, and Week 76 + 10 days
Reported as:
Mean · percent change
Adjusted Percent Change From Baseline in Femoral Neck, Total Hip, Trochanter, and Lumbar Spine BMD Via DXA at Week 52 + 10 Days and Week 76 + 10 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Week 52 + 10 days; Femoral neck (FN), n=70, 78-1.47 ± 0.5210.22 ± 0.512
Week 52 + 10 days; Total hip (TH), n=70, 78-1.62 ± 0.386-0.72 ± 0.379
Week 52 + 10 days; Trochanter (Tro.), n=70, 78-1.45 ± 0.602-1.04 ± 0.589
Week 52 + 10 days; Lumbar spine (LS), n=70, 76-1.41 ± 0.4160.04 ± 0.419
Week 76 + 10 days; FN, n=65, 70-1.91 ± 0.6240.31 ± 0.636
Week 76 + 10 days; TH, n=65, 70-1.70 ± 0.415-0.83 ± 0.420
Week 76 + 10 days; Tro., n=65, 70-2.14 ± 0.644-1.35 ± 0.650
Week 76 + 10 days; LS, n=65, 71-1.24 ± 0.4520.85 ± 0.457
Post-hocAdjusted Percent Change From Baseline in Femoral Neck, Total Hip, Trochanter, and Lumbar Spine BMD Via DXA at Week 52 + 30 Days and Week 76 + 30 Days

BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Percent change from Baseline at Week 52 + 30 days or Week 76 + 30 days was calculated as (BMD at Week 52 + 30 days (or Week 76 + 30 days) minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Baseline, Week 52 + 30 days, and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change From Baseline in Femoral Neck, Total Hip, Trochanter, and Lumbar Spine BMD Via DXA at Week 52 + 30 Days and Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Week 52 + 30 days; Femoral neck (FN), n=77, 83-1.59 ± 0.5030.24 ± 0.498
Week 52 + 30 days; Total hip (TH), n=77, 83-1.79 ± 0.370-0.72 ± 0.364
Week 52 + 30 days; Trochanter (Tro.), n=77, 83-1.83 ± 0.583-1.01 ± 0.574
Week 52 + 30 days; Lumbar spine (LS), n=79, 81-1.60 ± 0.4170.11 ± 0.421
Week 76 + 30 days; FN, n=66, 74-2.05 ± 0.6200.29 ± 0.619
Week 76 + 30 days; TH, n=66, 74-1.79 ± 0.408-0.68 ± 0.404
Week 76 + 30 days; Tro., n=66, 74-2.53 ± 0.508-0.96 ± 0.575
Week 76 + 30 days; LS, n=66, 72-1.15 ± 0.4641.13 ± 0.467
Post-hocAdjusted Percent Change From Baseline in Femoral Neck, Total Hip, Trochanter, and Intertrochanter Areal BMD Via Quantitative Computed Tomography (QCT) at Week 52 + 30 Days and Week 76 + 30 Days

BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by QCT. BMD by QCT is the 2-dimensional volume that mimics the DXA measurement for the same region. Percent change from Baseline at Week 52 + 30 days orWeek 76 + 30 days was calculated as (BMD at Week 52 + 30 days (orWeek 76 + 30 days) minus BMD at baseline)/BMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Baseline, Week 52 + 30 days, and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change From Baseline in Femoral Neck, Total Hip, Trochanter, and Intertrochanter Areal BMD Via Quantitative Computed Tomography (QCT) at Week 52 + 30 Days and Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Week 52 + 30 days; Femoral neck (FN), n=32, 35-2.39 ± 0.8950.09 ± 0.986
Week 52 + 30 days; Total hip (TH), n=32, 35-3.39 ± 0.4750.09 ± 0.521
Week 52 + 30 days; Trochanter (Tro.), n=32, 35-4.53 ± 0.612-0.23 ± 0.669
Week 52+30 days; Intertrochanter (Inter.),n=32, 35-3.36 ± 0.5150.77 ± 0.565
Week 76+30 days; Femoral neck (FN), n=31, 30-1.98 ± 0.587-1.52 ± 0.705
Week 76 + 30 days; TH, n=31, 30-2.11 ± 0.495-0.32 ± 0.591
Week 76 + 30 days; Tro., n=31, 30-2.86 ± 0.752-1.28 ± 0.892
Week 76 + 30 days; Inter., n=31, 30-1.66 ± 0.5250.30 ± 0.627
Post-hocAdjusted Percent Change in Femoral Neck, Total Hip, Trochanter, and Intertrochanter Areal BMD Via Quantitative Computed Tomography (QCT) From Week 52+30 Days to Week 76 + 30 Days

BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by QCT. BMD by QCT is the 2-dimensional volume that mimics the DXA measurement for the same region. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (BMD at Week 76 + 30 days minus BMD at Week 52 + 30 days)/BMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Week 52 + 30 days and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change in Femoral Neck, Total Hip, Trochanter, and Intertrochanter Areal BMD Via Quantitative Computed Tomography (QCT) From Week 52+30 Days to Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
percent change0.95 ± 0.728-1.39 ± 0.866
Total hip1.61 ± 0.346-0.18 ± 0.411
Trochanter1.81 ± 0.534-0.91 ± 0.632
Intertrochanter2.05 ± 0.428-0.25 ± 0.507
Post-hocAdjusted Percent Change From Baseline in Total Hip (TH) Integral, TH Trabecular, and TH Cortical vBMD Via QCT at Week 52 + 30 Days and at Week 76 + 30 Days

Volumetric (v)BMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. vBMD is the 3-dimensional density of a region of bone. Cortical bone is dense bone. Trabecular bone is spongy bone. Integral bone is the sum of cortical and trabecular bone measurements. Cortical thickness is the width of the cortical shell. Percent change from Baseline was calculated as (vBMD at Week 52+30 days (or Week 76+30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by ANCOVA with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Baseline, Week 52 + 30 days, and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change From Baseline in Total Hip (TH) Integral, TH Trabecular, and TH Cortical vBMD Via QCT at Week 52 + 30 Days and at Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Week 52 + 30 days; Integral, n=32, 35-3.60 ± 0.5870.99 ± 0.645
Week 52 + 30 days; Trabecular, n=32, 35-3.63 ± 1.2430.21 ± 1.376
Week 52 + 30 days; Cortical, n=32, 35-0.54 ± 0.5370.52 ± 0.603
Week 76 + 30 days; Integral, n=31, 30-1.70 ± 0.6570.85 ± 0.786
Week 76 + 30 days; Trabecular, n=31, 30-2.66 ± 1.2110.70 ± 1.445
Week 76 + 30 days; Cortical, n=31, 300.23 ± 0.4210.50 ± 0.518
Post-hocAdjusted Percent Change in Total Hip (TH) Integral, TH Trabecular, and TH Cortical vBMD Via QCT From Week 52+30 Days to Week 76 + 30 Days

Volumetric (v)BMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. vBMD is the 3-dimensional density of a region of bone. Cortical bone is dense bone. Trabecular bone is spongy bone. Integral bone is the sum of cortical and trabecular bone measurements. Cortical thickness is the width of the cortical shell. Percent change from Week 52 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/ vBMD at Week 52 + 30 days x 100% and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Week 52 + 30 days and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change in Total Hip (TH) Integral, TH Trabecular, and TH Cortical vBMD Via QCT From Week 52+30 Days to Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Integral2.24 ± 0.483-0.20 ± 0.5746
Trabecular0.90 ± 1.2521.15 ± 1.491
Cortical0.94 ± 0.449-0.06 ± 0.548
Post-hocAdjusted Percent Change From Baseline in Femoral Neck (FN) Integral, FN Trabecular, and FN Cortical vBMD Via QCT at Week 52 + 30 Days and Week 76 + 30 Days

vBMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Baseline at Week 52 + 30 days or Week 76 + 30 days was calculated as (vBMD at Week 52 + 30 days (orWeek 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Baseline, Week 52 + 30 days, and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change From Baseline in Femoral Neck (FN) Integral, FN Trabecular, and FN Cortical vBMD Via QCT at Week 52 + 30 Days and Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Week 52 + 30 days, Integral, n=32, 35-3.72 ± 1.0970.58 ± 1.208
Week 52 + 30 days, Trabecular, n=32, 35-1.83 ± 1.6950.91 ± 1.867
Week 52 + 30 days, Cortical, n=32, 35-1.00 ± 0.735-0.20 ± 0.819
Week 76 + 30 days, Integral, n=31, 30-2.13 ± 0.946-0.61 ± 1.141
Week 76 + 30 days, Trabecular, n=31, 30-1.05 ± 1.7982.27 ± 2.141
Week 76 + 30 days, Cortical, n=31, 30-0.46 ± 0.599-1.60 ± 0.723
Post-hocAdjusted Percent Change in Femoral Neck (FN) Integral, FN Trabecular, and FN Cortical vBMD Via QCT From Week 52+30 Days to Week 76 + 30 Days

vBMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Week 52 + 30 days and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change in Femoral Neck (FN) Integral, FN Trabecular, and FN Cortical vBMD Via QCT From Week 52+30 Days to Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Integral2.21 ± 0.871-1.37 ± 1.040
Trabecular0.27 ± 1.7212.21 ± 2.044
Cortical1.03 ± 0.774-1.30 ± 0.929
Post-hocAdjusted Percent Change From Baseline in Trochanter Integral, Trochanter Trabecular, and Trochanter Cortical vBMD Via QCT at Week 52 + 30 Days and Week 76 + 30 Days

vBMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Baseline at Week 52 + 30 days or Week 76 + 30 days was calculated as (vBMD at Week 52 + 30 days (or Week 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Baseline, Week 52 + 30 days, and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change From Baseline in Trochanter Integral, Trochanter Trabecular, and Trochanter Cortical vBMD Via QCT at Week 52 + 30 Days and Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Week 52 + 30 days, Integral, n=32, 35-4.80 ± 0.6660.01 ± 0.730
Week 52 + 30 days, Trabecular, n=32, 35-3.43 ± 1.1570.67 ± 1.275
Week 52 + 30 days, Cortical, n=32, 35-1.26 ± 0.490-0.18 ± 0.540
Week 76 + 30 days, Integral, n=31, 30-2.88 ± 0.748-0.93 ± 0.889
Week 76 + 30 days, Trabecular, n=31, 30-2.42 ± 1.0850.92 ± 1.293
Week 76 + 30 days, Cortical, n=31, 30-0.49 ± 0.384-0.64 ± 0.462
Post-hocAdjusted Percent Change in Trochanter Integral, Trochanter Trabecular, and Trochanter Cortical vBMD Via QCT From Week 52+30 Days to Week 76 + 30 Days

vBMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Week 52 + 30 days and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change in Trochanter Integral, Trochanter Trabecular, and Trochanter Cortical vBMD Via QCT From Week 52+30 Days to Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
percent change2.22 ± 0.506-0.90 ± 0.600
Trabecular1.07 ± 1.1380.95 ± 1.353
Cortical0.78 ± 0.396-0.65 ± 0.474
Post-hocAdjusted Percent Change From Baseline in Intertrochanter Integral, Intertrochanter Trabecular, and Intertrochanter Cortical vBMD Via QCT at Week 52 + 30 Days and Week 76 + 30 Days

vBMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Baseline at Week 52 + 30 days or Week 76 + 30 days was calculated as (vBMD at Week 52 + 30 days (or Week 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Baseline, Week 52 + 30 days, and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change From Baseline in Intertrochanter Integral, Intertrochanter Trabecular, and Intertrochanter Cortical vBMD Via QCT at Week 52 + 30 Days and Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Week 52 + 30 days, Integral, n=32, 35-3.47 ± 0.6212.18 ± 0.683
Week 52 + 30 days, Trabecular, n=32, 35-4.26 ± 1.341-0.22 ± 1.485
Week 52 + 30 days, Cortical, n=32, 35-0.76 ± 0.5680.99 ± 0.631
Week 76 + 30 days, Integral, n=31, 30-0.92 ± 0.7461.88 ± 0.895
Week 76 + 30 days, Trabecular, n=31, 30-3.09 ± 1.2780.27 ± 1.525
Week 76 + 30 days, Cortical, n=31, 300.41 ± 0.4720.79 ± 0.573
Post-hocAdjusted Percent Change in Intertrochanter Integral, Intertrochanter Trabecular, and Intertrochanter Cortical vBMD Via QCT From Week 52+30 Days to Week 76 + 30 Days

vBMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Week 52 + 30 days and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change in Intertrochanter Integral, Intertrochanter Trabecular, and Intertrochanter Cortical vBMD Via QCT From Week 52+30 Days to Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
percent change2.83 ± 0.563-0.46 ± 0.671
Trabecular1.16 ± 1.2981.21 ± 1.545
Cortical1.29 ± 0.479-0.27 ± 0.577
Post-hocAdjusted Percent Change From Baseline in Vertebral Trabecular vBMD Via QCT at Week 52 + 30 Days and Week 76 + 30 Days

BMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Baseline at Week 52 + 30 days or Week 76 + 30 days was calculated as (vBMD at Week 52 + 30 days (orWeek 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Baseline, Week 52 + 30 days, and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change From Baseline in Vertebral Trabecular vBMD Via QCT at Week 52 + 30 Days and Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Week 52 + 30 days, n=32, 35-6.71 ± 1.454-1.72 ± 1.601
Week 76 + 30 days, n=31, 30-5.15 ± 1.121-3.91 ± 1.337
Post-hocAdjusted Percent Change in Vertebral Trabecular vBMD Via QCT From Week 52+30 Days to Week 76 + 30 Days

BMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Week 52 + 30 days and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change in Vertebral Trabecular vBMD Via QCT From Week 52+30 Days to Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Adjusted Percent Change in Vertebral Trabecular vBMD Via QCT From Week 52+30 Days to Week 76 + 30 Days3.53 ± 1.454-2.11 ± 1.727
Post-hocAdjusted Percent Change From Baseline in Femoral Neck (FN) Supero-posterior Integral, Trabecular, and Cortical vBMD Via QCT at Week 52 + 30 Days and Week 76 + 30 Days

vBMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Baseline at Week 52 + 30 days orWeek 76 + 30 days was calculated as (vBMD at Week 52 + 30 days (or Week 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therpay, and region. Supero-posterior is the upper and back section of the FN.

Time frame:
Baseline, Week 52 + 30 days, and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change From Baseline in Femoral Neck (FN) Supero-posterior Integral, Trabecular, and Cortical vBMD Via QCT at Week 52 + 30 Days and Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Week 52 + 30 days, Integral, n=32, 35-10.26 ± 2.194-0.03 ± 2.417
Week 52 + 30 days, Trabecular, n=32, 352.77 ± 5.8485.57 ± 6.420
Week 52 + 30 days, Cortical, n=32, 35-3.76 ± 0.836-0.66 ± 0.922
Week 76 + 30 days, Integral, n=31, 30-4.21 ± 2.0941.07 ± 2.508
Week 76 + 30 days, Trabecular, n=31, 302.37 ± 7.04010.24 ± 8.362
Week 76 + 30 days, Cortical, n=31, 30-1.65 ± 0.730-1.30 ± 0.877
Post-hocAdjusted Change From Baseline in Femoral Neck (FN) Supero-posterior and Cortical vBMD Via QCT at Week 76 + 30 Days

vBMD was measured by QCT. Change from Baseline at Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at baseline and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Supero-posterior is the upper and back section of the FN.

Time frame:
Baseline and Week 76 + 30 days
Reported as:
Mean · mg/cm^3
Adjusted Change From Baseline in Femoral Neck (FN) Supero-posterior and Cortical vBMD Via QCT at Week 76 + 30 Days
mg/cm^3Rosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Adjusted Change From Baseline in Femoral Neck (FN) Supero-posterior and Cortical vBMD Via QCT at Week 76 + 30 Days-8.007 ± 3.4199-7.006 ± 4.1114
Post-hocAdjusted Percent Change in Femoral Neck (FN) Supero-posterior Integral, Trabecular, and Cortical vBMD Via QCT From Week 52+30 Days to Week 76 + 30 Days

vBMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therpay, and region. Supero-posterior is the upper and back section of the FN.

Time frame:
Week 52 + 30 days and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change in Femoral Neck (FN) Supero-posterior Integral, Trabecular, and Cortical vBMD Via QCT From Week 52+30 Days to Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Integral8.29 ± 3.2620.52 ± 3.884
Trabecular36.05 ± 31.815-11.69 ± 37.721
Cortical2.17 ± 0.944-0.94 ± 1.129
Post-hocAdjusted Change in Femoral Neck (FN) Supero-posterior Cortical vBMD Via QCT From Week 52 + 30 Days to Week 76 + 30 Days

vBMD was measured by QCT. Change from Week 52 + 30 days to Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therpay, and region. Supero-posterior is the upper and back section of the FN.

Time frame:
Week 52 + 30 days and Week 76 + 30 days
Reported as:
Mean · mg/cm^3
Adjusted Change in Femoral Neck (FN) Supero-posterior Cortical vBMD Via QCT From Week 52 + 30 Days to Week 76 + 30 Days
mg/cm^3Rosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Adjusted Change in Femoral Neck (FN) Supero-posterior Cortical vBMD Via QCT From Week 52 + 30 Days to Week 76 + 30 Days9.30 ± 4.287-4.92 ± 5.130
Post-hocAdjusted Percent Change From Baseline in Femoral Neck (FN) Supero-posterior Cortical Thickness Via QCT at Week 52 + 30 Days and Week 76 + 30 Days

Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 52 + 30 days (or Week 76 + 30 days) minus thickness at Baseline)/thickness at Baseline x 100%

Time frame:
Baseline, Week 52 + 30 days, and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change From Baseline in Femoral Neck (FN) Supero-posterior Cortical Thickness Via QCT at Week 52 + 30 Days and Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Week 52 + 30 days, n=32, 35-20.48 ± 3.6141.00 ± 3.986
Week 76 + 30 days, n=31,30-3.52 ± 3.674-1.50 ± 4.423
Post-hocAdjusted Change From Baseline in Femoral Neck (FN) Supero-posterior Cortical Thickness Via QCT at Week 76 + 30 Days

Cortical thickness was measured by QCT. Change from baseline was calculated as thickness at Week 76 + 30 days minus thickness at Baseline.

Time frame:
Baseline and Week 76 + 30 days
Reported as:
Mean · millimeters
Adjusted Change From Baseline in Femoral Neck (FN) Supero-posterior Cortical Thickness Via QCT at Week 76 + 30 Days
millimetersRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Adjusted Change From Baseline in Femoral Neck (FN) Supero-posterior Cortical Thickness Via QCT at Week 76 + 30 Days-0.95 ± 0.0537-0.067 ± 0.0647
Post-hocAdjusted Percent Change in Femoral Neck (FN) Supero-posterior Cortical Thickness Via QCT From Week 52+30 Days to Week 76 + 30 Days

Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days)/thickness at Week 52 + 30 days x 100%.

Time frame:
Week 52 + 30 days and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change in Femoral Neck (FN) Supero-posterior Cortical Thickness Via QCT From Week 52+30 Days to Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Adjusted Percent Change in Femoral Neck (FN) Supero-posterior Cortical Thickness Via QCT From Week 52+30 Days to Week 76 + 30 Days32.42 ± 10.358-7.80 ± 2.383
Post-hocAdjusted Change in Femoral Neck (FN) Supero-posterior Cortical Thickness Via QCT From Week 52 + 30 Days to Week 76 + 30 Days

Cortical thickness was measured by QCT. Change was calculated as thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days.

Time frame:
Week 52 + 30 days and Week 76 + 30 days
Reported as:
Mean · millimeters
Adjusted Change in Femoral Neck (FN) Supero-posterior Cortical Thickness Via QCT From Week 52 + 30 Days to Week 76 + 30 Days
millimetersRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Adjusted Change in Femoral Neck (FN) Supero-posterior Cortical Thickness Via QCT From Week 52 + 30 Days to Week 76 + 30 Days0.18 ± 0.049-0.05 ± 0.059
Post-hocAdjusted Percent Change From Baseline in Femoral Neck (FN) Supero-anterior Integral, Trabecular, and Cortical vBMD Via QCT at Week 52 + 30 Days and Week 76 + 30 Days

vBMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Baseline at Week 52 + 30 daysor Week 76 + 30 days was calculated as (vBMD at Week 52 + 30 days(or Week 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Supero-anterior is the upper and front section of the FN.

Time frame:
Baseline, Week 52 plus 30 days, and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change From Baseline in Femoral Neck (FN) Supero-anterior Integral, Trabecular, and Cortical vBMD Via QCT at Week 52 + 30 Days and Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Week 52 + 30 days, Integral, n=32, 35-6.56 ± 2.106-0.58 ± 2.311
Week 52 + 30 days, Trabecular, n=32, 353.59 ± 4.7192.82 ± 5.180
Week 52 + 30 days, Cortical, n=32, 35-1.91 ± 0.901-0.25 ± 0.977
Week 76 + 30 days, Integral, n=31, 30-4.97 ± 2.384-2.45 ± 2.838
Week 76 + 30 days, Trabecular, n=31, 30-0.85 ± 6.0503.98 ± 7.171
Week 76 + 30 days, Cortical, n=31, 30-0.93 ± 0.745-1.49 ± 0.876
Post-hocAdjusted Change From Baseline in Femoral Neck (FN) Supero-anterior Cortical vBMD Via QCT at Week 76 + 30 Days

vBMD was measured by QCT. Change from Baseline at Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at baseline and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Supero-anterior is the upper and front section of the FN.

Time frame:
Baseline and Week 76 + 30 days
Reported as:
Mean · mg/cm^3
Adjusted Change From Baseline in Femoral Neck (FN) Supero-anterior Cortical vBMD Via QCT at Week 76 + 30 Days
mg/cm^3Rosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Adjusted Change From Baseline in Femoral Neck (FN) Supero-anterior Cortical vBMD Via QCT at Week 76 + 30 Days-4.555 ± 3.5006-7.553 ± 4.1177
Post-hocAdjusted Percent Change in Femoral Neck (FN) Supero-anterior Integral, Trabecular, and Cortical vBMD Via QCT From Week 52+30 Days to Week 76 + 30 Days

vBMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Supero-anterior is the upper and front section of the FN.

Time frame:
Week 52 + 30 days and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change in Femoral Neck (FN) Supero-anterior Integral, Trabecular, and Cortical vBMD Via QCT From Week 52+30 Days to Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Integral2.96 ± 2.202-1.81 ± 2.609
Trabecular-2.78 ± 4.6776.63 ± 5.531
Cortical1.19 ± 0.778-1.28 ± 0.912
Post-hocAdjusted Change in Femoral Neck (FN) Supero-anterior Cortical vBMD Via QCT From Week 52+30 Days to Week 76 + 30 Days

vBMD was measured by QCT. Change from Week 52 + 30 days to Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Supero-anterior is the upper and front section of the FN.

Time frame:
Week 52 + 30 days and Week 76 + 30 days
Reported as:
Mean · mg/cm^3
Adjusted Change in Femoral Neck (FN) Supero-anterior Cortical vBMD Via QCT From Week 52+30 Days to Week 76 + 30 Days
mg/cm^3Rosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Adjusted Change in Femoral Neck (FN) Supero-anterior Cortical vBMD Via QCT From Week 52+30 Days to Week 76 + 30 Days5.19 ± 3.686-6.24 ± 4.319
Post-hocAdjusted Percent Change From Baseline in Femoral Neck (FN) Supero-anterior Cortical Thickness Via QCT at Week 52 + 30 Days and Week 76 + 30 Days

Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 52 + 30 days(or Week 76 + 30 days) minus thickness at Baseline)/thickness at Baseline x 100%.

Time frame:
Baseline, Week 52 + 30 days, and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change From Baseline in Femoral Neck (FN) Supero-anterior Cortical Thickness Via QCT at Week 52 + 30 Days and Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Week 52 + 30 days, n=32, 35-13.45 ± 5.0025.05 ± 5.453
Week 76 + 30 days, n=31, 30-4.23 ± 4.491-4.78 ± 5.327
Post-hocAdjusted Change From Baseline in Femoral Neck (FN) Supero-anterior Cortical Thickness Via QCT at Week 76 + 30 Days

Cortical thickness was measured by QCT. Change from baseline was calculated as thickness at Week 76 + 30 days minus thickness at Baseline.

Time frame:
Baseline and Week 76 + 30 days
Reported as:
Mean · millimeters
Adjusted Change From Baseline in Femoral Neck (FN) Supero-anterior Cortical Thickness Via QCT at Week 76 + 30 Days
millimetersRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Adjusted Change From Baseline in Femoral Neck (FN) Supero-anterior Cortical Thickness Via QCT at Week 76 + 30 Days-0.117 ± 0.0484-0.087 ± 0.0575
Post-hocAdjusted Percent Change in Femoral Neck (FN) Supero-anterior Cortical Thickness Via QCT From Week 52 + 30 Days to Week 76 + 30 Days

Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days)/thickness at Week 52 + 30 days x 100%.

Time frame:
Week 52 + 30 days and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change in Femoral Neck (FN) Supero-anterior Cortical Thickness Via QCT From Week 52 + 30 Days to Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Adjusted Percent Change in Femoral Neck (FN) Supero-anterior Cortical Thickness Via QCT From Week 52 + 30 Days to Week 76 + 30 Days14.02 ± 6.779-13.65 ± 7.995
Post-hocAdjusted Change in Femoral Neck (FN) Supero-anterior Cortical Thickness Via QCT From Week 52+30 Days to Week 76 + 30 Days

Cortical thickness was measured by QCT. Change was calculated as thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days.

Time frame:
Week 52 + 30 days and Week 76 + 30 days
Reported as:
Mean · millimeters
Adjusted Change in Femoral Neck (FN) Supero-anterior Cortical Thickness Via QCT From Week 52+30 Days to Week 76 + 30 Days
millimetersRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Adjusted Change in Femoral Neck (FN) Supero-anterior Cortical Thickness Via QCT From Week 52+30 Days to Week 76 + 30 Days0.11 ± 0.052-0.13 ± 0.061
Post-hocAdjusted Percent Change From Baseline in Femoral Neck (FN) Infero-posterior Integral, Trabecular, and Cortical vBMD Via QCT at Week 52 + 30 Days and Week 76 + 30 Days

vBMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Baseline at Week 52 + 30 days or Week 76 + 30 days was calculated as (vBMD at Week 52 + 30 days (or Week 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-posterior is the lower and back section of the FN.

Time frame:
Baseline, Week 52 + 30 days, and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change From Baseline in Femoral Neck (FN) Infero-posterior Integral, Trabecular, and Cortical vBMD Via QCT at Week 52 + 30 Days and Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Week 52 + 30 days, Integral, n=32, 35-4.11 ± 1.0741.74 ± 1.200
Week 52 + 30 days, Trabecular, n=32, 35-84.08 ± 270.700282.16 ± 297.445
Week 52 + 30 days, Cortical, n=32, 35-3.42 ± 1.5311.14 ± 1.694
Week 76 + 30 days, Integral, n=31, 30-3.11 ± 0.9330.01 ± 1.147
Week 76 + 30 days, Trabecular, n=31, 3024.46 ± 17.47313.54 ± 20.790
Week 76 + 30 days, Cortical, n=31, 30-1.32 ± 1.234-1.17 ± 1.492
Post-hocAdjusted Change From Baseline in Femoral Neck (FN) Infero-posterior Cortical vBMD Via QCT at Week 76 + 30 Days

vBMD was measured by QCT. Change from Baseline at Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at baseline and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-posterior is the lower and back section of the FN.

Time frame:
Baseline and Week 76 + 30 days
Reported as:
Mean · mg/cm^3
Adjusted Change From Baseline in Femoral Neck (FN) Infero-posterior Cortical vBMD Via QCT at Week 76 + 30 Days
mg/cm^3Rosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Adjusted Change From Baseline in Femoral Neck (FN) Infero-posterior Cortical vBMD Via QCT at Week 76 + 30 Days-12.424 ± 8.9945-10.244 ± 10.8703
Post-hocAdjusted Percent Change in Femoral Neck (FN) Infero-posterior Integral, Trabecular, and Cortical vBMD Via QCT From Week 52+30 Days to Week 76 + 30 Days

vBMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-posterior is the lower and back section of the FN.

Time frame:
Week 52 + 30 days and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change in Femoral Neck (FN) Infero-posterior Integral, Trabecular, and Cortical vBMD Via QCT From Week 52+30 Days to Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Integral1.47 ± 1.183-1.87 ± 1.435
Trabecular-39.81 ± 130.071161.81 ± 154.179
Cortical2.67 ± 1.728-2.50 ± 2.076
Post-hocAdjusted Change in Femoral Neck (FN) Infero-posterior Cortical vBMD Via QCT From Week 52 + 30 Days to Week 76 + 30 Days

vBMD was measured by QCT. Change from Week 52 + 30 days to Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-posterior is the lower and back section of the FN.

Time frame:
Week 52 + 30 days and Week 76 + 30 days
Reported as:
Mean · mg/cm^3
Adjusted Change in Femoral Neck (FN) Infero-posterior Cortical vBMD Via QCT From Week 52 + 30 Days to Week 76 + 30 Days
mg/cm^3Rosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Adjusted Change in Femoral Neck (FN) Infero-posterior Cortical vBMD Via QCT From Week 52 + 30 Days to Week 76 + 30 Days15.48 ± 11.544-17.59 ± 13.865
Post-hocAdjusted Percent Change From Baseline in Femoral Neck (FN) Infero-posterior Cortical Thickness Via QCT at Week 52 + 30 Days and Week 76 + 30 Days

Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 52 + 30 days (or Week 76 + 30 days) minus thickness at Baseline)/thickness at Baseline x 100%.

Time frame:
Baseline, Week 52 + 30 days, and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change From Baseline in Femoral Neck (FN) Infero-posterior Cortical Thickness Via QCT at Week 52 + 30 Days and Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Week 52 + 30 days, n=32, 350.47 ± 1.977-1.27 ± 2.180
Week 76 + 30 days, n=31, 30-1.46 ± 1.593-0.11 ± 1.910
Post-hocAdjusted Change From Baseline in Femoral Neck (FN) Infero-posterior Cortical Thickness Via QCT at Week 76 + 30 Days

Cortical thickness was measured by QCT. Change from Baseline was calculated as thickness at Week 76 + 30 days minus thickness at Baseline.

Time frame:
Baseline and Week 76 + 30 days
Reported as:
Mean · millimeters
Adjusted Change From Baseline in Femoral Neck (FN) Infero-posterior Cortical Thickness Via QCT at Week 76 + 30 Days
millimetersRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Adjusted Change From Baseline in Femoral Neck (FN) Infero-posterior Cortical Thickness Via QCT at Week 76 + 30 Days-0.082 ± 0.0816-0.048 ± 0.0978
Post-hocAdjusted Percent Change in Femoral Neck (FN) Infero-posterior Cortical Thickness Via QCT From Week 52 + 30 Days to Week 76 + 30 Days

Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days)/thickness at Week 52 + 30 days x 100%.

Time frame:
Week 52 + 30 days and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change in Femoral Neck (FN) Infero-posterior Cortical Thickness Via QCT From Week 52 + 30 Days to Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Adjusted Percent Change in Femoral Neck (FN) Infero-posterior Cortical Thickness Via QCT From Week 52 + 30 Days to Week 76 + 30 Days-1.48 ± 1.5522.04 ± 1.846
Post-hocAdjusted Change in Femoral Neck (FN) Infero-posterior Cortical Thickness Via QCT From Week 52 + 30 Days to Week 76 + 30 Days

Cortical thickness was measured by QCT. Change was calculated as thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days.

Time frame:
Week 52 + 30 days and Week 76 + 30 days
Reported as:
Mean · millimeters
Adjusted Change in Femoral Neck (FN) Infero-posterior Cortical Thickness Via QCT From Week 52 + 30 Days to Week 76 + 30 Days
millimetersRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Adjusted Change in Femoral Neck (FN) Infero-posterior Cortical Thickness Via QCT From Week 52 + 30 Days to Week 76 + 30 Days-0.08 ± 0.0780.07 ± 0.093
Post-hocAdjusted Percent Change From Baseline in Femoral Neck (FN) Infero-anterior Integral, Trabecular, and Cortical vBMD Via QCT at Week 52 + 30 Days and Week 76 + 30 Days

vBMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Baseline at Week 52 + 30 days or Week 76 + 30 days was calculated as (vBMD at Week 52 + 30 days (orWeek 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-anterior is the lower and front section of the FN.

Time frame:
Baseline, Week 52 + 30 days, and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change From Baseline in Femoral Neck (FN) Infero-anterior Integral, Trabecular, and Cortical vBMD Via QCT at Week 52 + 30 Days and Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Week 52 + 30 days, Integral, n=32, 35-4.35 ± 1.9501.26 ± 2.163
Week 52, Trabecular, n=32, 35-161.59 ± 774.589930.71 ± 851.727
Week 52, Cortical, n=32, 35-1.85 ± 1.3090.85 ± 1.563
Week 76 + 30 days, Integral, n=31, 30-0.29 ± 2.3010.54 ± 2.810
Week 76 + 30 days, Trabecular, n=31, 3081.29 ± 35.95937.81 ± 42.791
Week 76 + 30 days, Cortical, n=31, 301.45 ± 1.149-0.63 ± 1.409
Post-hocAdjusted Change From Baseline in Femoral Neck (FN) Infero-anterior Cortical vBMD Via QCT at Week 76 + 30 Days

vBMD was measured by QCT. Change from Baseline at Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at baseline and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-anterior is the lower and front section of the FN.

Time frame:
Baseline and Week 76 + 30 days
Reported as:
Mean · mg/cm^3
Adjusted Change From Baseline in Femoral Neck (FN) Infero-anterior Cortical vBMD Via QCT at Week 76 + 30 Days
mg/cm^3Rosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Adjusted Change From Baseline in Femoral Neck (FN) Infero-anterior Cortical vBMD Via QCT at Week 76 + 30 Days7.901 ± 6.9912-5.025 ± 8.5722
Post-hocAdjusted Percent Change in Femoral Neck (FN) Infero-anterior Integral, Trabecular, and Cortical vBMD Via QCT From Week 52+30 Days to Week 76 + 30 Days

vBMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-anterior is the lower and front section of the FN.

Time frame:
Week 52 + 30 days and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change in Femoral Neck (FN) Infero-anterior Integral, Trabecular, and Cortical vBMD Via QCT From Week 52+30 Days to Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Integral5.05 ± 1.8780.38 ± 2.268
Trabecular-90.60 ± 167.792260.13 ± 199.323
Cortical3.68 ± 1.649-1.64 ± 2.016
Post-hocAdjusted Change in Femoral Neck (FN) Infero-anterior Cortical vBMD Via QCT From Week 52 + 30 Days to Week 76 + 30 Days

vBMD was measured by QCT. Change from Week 52 + 30 days to Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-anterior is the lower and front section of the FN.

Time frame:
Week 52 + 30 days and Week 76 + 30 days
Reported as:
Mean · mg/cm^3
Adjusted Change in Femoral Neck (FN) Infero-anterior Cortical vBMD Via QCT From Week 52 + 30 Days to Week 76 + 30 Days
mg/cm^3Rosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Adjusted Change in Femoral Neck (FN) Infero-anterior Cortical vBMD Via QCT From Week 52 + 30 Days to Week 76 + 30 Days20.15 ± 9.677-10.73 ± 11.830
Post-hocAdjusted Percent Change From Baseline in Femoral Neck (FN) Infero-anterior Cortical Thickness Via QCT at Week 52 + 30 Days and Week 76 + 30 Days

Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 52 + 30 days (orWeek 76 + 30 days) minus thickness at Baseline)/thickness at Baseline x 100%.

Time frame:
Baseline, Week 52 + 30 days, and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change From Baseline in Femoral Neck (FN) Infero-anterior Cortical Thickness Via QCT at Week 52 + 30 Days and Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Week 52 + 30 days, n=32, 35-6.05 ± 2.3930.64 ± 2.656
Week 76 + 30 days, n=31, 30-3.59 ± 2.8040.39 ± 3.421
Post-hocAdjusted Change From Baseline in Femoral Neck (FN) Infero-anterior Cortical Thickness Via QCT at Week 76 + 30 Days

Cortical thickness was measured by QCT. Change was calculated as thickness at Week 76 + 30 days minus thickness at Baseline.

Time frame:
Baseline and Week 76 + 30 days
Reported as:
Mean · millimeters
Adjusted Change From Baseline in Femoral Neck (FN) Infero-anterior Cortical Thickness Via QCT at Week 76 + 30 Days
millimetersRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Adjusted Change From Baseline in Femoral Neck (FN) Infero-anterior Cortical Thickness Via QCT at Week 76 + 30 Days-0.120 ± 0.0931-0.040 ± 0.1135
Post-hocAdjusted Percent Change in Femoral Neck (FN) Infero-anterior Cortical Thickness Via QCT From Week 52 + 30 Days to Week 76 + 30 Days

Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days)/thickness at Week 52 + 30 days x 100%.

Time frame:
Week 52 + 30 days and Week 76 + 30 days
Reported as:
Mean · percent change
Adjusted Percent Change in Femoral Neck (FN) Infero-anterior Cortical Thickness Via QCT From Week 52 + 30 Days to Week 76 + 30 Days
percent changeRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Adjusted Percent Change in Femoral Neck (FN) Infero-anterior Cortical Thickness Via QCT From Week 52 + 30 Days to Week 76 + 30 Days3.12 ± 2.1271.56 ± 2.257
Post-hocAdjusted Change in Femoral Neck (FN) Infero-anterior Cortical Thickness Via QCT From Week 52 + 30 Days to Week 76 + 30 Days

Cortical thickness was measured by QCT. Change was calculated as thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days.

Time frame:
Week 52 + 30 days and Week 76 + 30 days
Reported as:
Mean · millimeters
Adjusted Change in Femoral Neck (FN) Infero-anterior Cortical Thickness Via QCT From Week 52 + 30 Days to Week 76 + 30 Days
millimetersRosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Adjusted Change in Femoral Neck (FN) Infero-anterior Cortical Thickness Via QCT From Week 52 + 30 Days to Week 76 + 30 Days0.09 ± 0.0650.01 ± 0.078
Post-hocAdjusted Change From Baseline in Albumin-adjusted Serum Calcium (AASC) at Week 52 and Week 76

AASC levels were measured from blood samples. AASC is the amount of free calcium circulating in the blood and calcium is required for good bone health. Change from baseline was calculated as the Week 52or Week 76 value minus the baseline value and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Baseline, Week 52, and Week 76
Reported as:
Mean · millimoles per Liter (mmol/L)
Adjusted Change From Baseline in Albumin-adjusted Serum Calcium (AASC) at Week 52 and Week 76
millimoles per Liter (mmol/L)Rosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Week 52, n=73, 830.01 ± 0.0090.03 ± 0.009
Week 76, n=64, 750.03 ± 0.0100.04 ± 0.010
Post-hocAdjusted Change in Albumin-adjusted Serum Calcium (AASC) From Week 52 to Week 76

AASC levels were measured from blood samples. AASC is the amount of free calcium circulating in the blood and calcium is required for good bone health. Change from Week 52 was calculated as the Week 76 value minus the Week 52 value and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.

Time frame:
Week 52 and Week 76
Reported as:
Mean · millimoles per Liter (mmol/L)
Adjusted Change in Albumin-adjusted Serum Calcium (AASC) From Week 52 to Week 76
millimoles per Liter (mmol/L)Rosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL Period
Adjusted Change in Albumin-adjusted Serum Calcium (AASC) From Week 52 to Week 760.01 ± 0.0110.00 ± 0.010

Adverse events

Collected over 76 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rosiglitazone: DB—7/114 (6.1%)47/115 (40.9%)
Metformin: DB—5/111 (4.5%)45/111 (40.5%)
Rosiglitazone: MET OL—0/76 (0%)12/76 (15.8%)
Metformin: MET OL—0/84 (0%)8/84 (9.5%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventRosiglitazone: DBMetformin: DBRosiglitazone: MET OLMetformin: MET OL
Urinary tract infectionInfections and infestations1/1141/1110/760/84
Enteritis infectiousInfections and infestations0/1141/1110/760/84
Cerebral infarctionNervous system disorders0/1141/1110/760/84
AsthmaRespiratory, thoracic and mediastinal disorders0/1141/1110/760/84
Coronary artery diseaseCardiac disorders0/1141/1110/760/84
Wrist fractureInjury, poisoning and procedural complications0/1141/1110/760/84
Alanine aminotransferase increasedInvestigations0/1141/1110/760/84
Device dislocationGeneral disorders1/1140/1110/760/84
Generalised oedemaGeneral disorders1/1140/1110/760/84
Sudden cardiac deathGeneral disorders1/1140/1110/760/84
Most frequent other events
Showing 10 of 12
Most frequent other events
EventRosiglitazone: DBMetformin: DBRosiglitazone: MET OLMetformin: MET OL
Oedemal peripheralGeneral disorders17/1150/1110/760/84
DiarrhoeaGastrointestinal disorders3/11515/1116/761/84
HeadacheNervous system disorders9/1155/1111/761/84
Weight increasedInvestigations9/1151/1110/760/84
NasopharyngitisInfections and infestations7/1157/1111/760/84
NauseaGastrointestinal disorders3/1153/1113/765/84
DyspepsiaGastrointestinal disorders2/1156/1110/760/84
InfluenzaInfections and infestations3/1156/1110/761/84
ArthralgiaMusculoskeletal and connective tissue disorders5/1156/1111/760/84
FatigueGeneral disorders6/1154/1110/760/84

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Rosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL PeriodTotal
Mean63.6 ± 6.6164.0 ± 6.4663.8 ± 6.52
Sex: Female, Male
Sex: Female, Male(Participants)Rosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL PeriodTotal
Female114111225
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Rosiglitazone in DB Period; Metformin in OL PeriodMetformin in DB Period; Metformin in OL PeriodTotal
White - White/Caucasian/European8278160
African American/African2810
American Indian or Alaskan Native6511
Asian - Central/South Asian131023
South East Asian4610
Mixed Race325
East Asia426
08

Study locations

42 sites
  • GSK Investigational Site
    Tucson, Arizona 85745, United States
  • GSK Investigational Site
    Huntington Park, California 90255, United States
  • GSK Investigational Site
    Los Angeles, California 90022, United States
  • GSK Investigational Site
    Sacramento, California 95823, United States
  • GSK Investigational Site
    San Diego, California 92117, United States
  • GSK Investigational Site
    Torrance, California 90502, United States
  • GSK Investigational Site
    Vista, California 92081, United States
  • GSK Investigational Site
    Miami, Florida 33143, United States
  • GSK Investigational Site
    Miami, Florida 33156, United States
  • GSK Investigational Site
    Lexington, Kentucky 40504, United States
  • GSK Investigational Site
    Slidell, Louisiana 70461, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89117, United States
  • GSK Investigational Site
    Albuquerque, New Mexico 87102, United States
  • GSK Investigational Site
    Albuquerque, New Mexico 87106, United States
  • GSK Investigational Site
    East Syracuse, New York 13057, United States
  • GSK Investigational Site
    Kingston, New York 12401, United States
  • GSK Investigational Site
    Columbia, South Carolina 29201, United States
  • GSK Investigational Site
    Columbia, South Carolina 29204, United States
  • GSK Investigational Site
    Kingsport, Tennessee 37660, United States
  • GSK Investigational Site
    San Antonio, Texas 78221, United States
  • GSK Investigational Site
    Wenatchee, Washington 98801, United States
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires B1704ETD, Argentina
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1012AAR, Argentina
  • GSK Investigational Site
    Buenos Aires, 1425, Argentina
  • GSK Investigational Site
    Ciudad Autónoma de Buenos Aires, C1128AAF, Argentina
  • GSK Investigational Site
    Vancouver, British Columbia V6H 3X8, Canada
  • GSK Investigational Site
    Brampton, Ontario L6T 3T1, Canada
  • GSK Investigational Site
    Granby, Quebec J2G 8Z9, Canada
  • GSK Investigational Site
    Tallinn, 13415, Estonia
  • GSK Investigational Site
    Tallin, 13419, Estonia
  • GSK Investigational Site
    Cuernavaca, Morelos 62250, Mexico
  • GSK Investigational Site
    Monterrey, Nuevo León 64460, Mexico
  • GSK Investigational Site
    Mérida, Yucatán 97129, Mexico
  • GSK Investigational Site
    Durango, 34000, Mexico
  • GSK Investigational Site
    Lahore, 54000, Pakistan
  • GSK Investigational Site
    Manila, 01008, Philippines
  • GSK Investigational Site
    Marikina City, 1810, Philippines
  • GSK Investigational Site
    Alicante, 03114, Spain
  • GSK Investigational Site
    Benidorm/Alicante, 03503, Spain
  • GSK Investigational Site
    Granada, 18003, Spain
  • GSK Investigational Site
    Granada, 18014, Spain
  • GSK Investigational Site
    Petrer, 03610, Spain
09

References and documents

Publications

  • Fitzpatrick LA, Bilezikian JP, Wooddell M, Paul G, Kolatkar NS, Nino AJ, Miller CG, Bogado CE, Arnaud CD, Cobitz AR. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. J Drug Assess. 2011 Dec 16;1(1):11-9. doi: 10.3109/21556660.2011.641703. eCollection 2012. PubMed 27536422 ↗
  • Gnesin F, Thuesen ACB, Kahler LKA, Madsbad S, Hemmingsen B. Metformin monotherapy for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2. PubMed 32501595 ↗
  • Miller CG, Bogado CC, Nino AJ, Northcutt AR, Yu HJ, Lewiecki EM, Paul G, Cobitz AR, Wooddell MJ, Bilezikian JP, Fitzpatrick LA. Evaluation of Quantitative Computed Tomography Cortical Hip Quadrant in a Clinical Trial With Rosiglitazone: A Potential New Study Endpoint. J Clin Densitom. 2016 Oct;19(4):485-491. doi: 10.1016/j.jocd.2016.02.003. Epub 2016 Mar 24. PubMed 27052635 ↗
  • Bilezikian JP, Josse RG, Eastell R, Lewiecki EM, Miller CG, Wooddell M, Northcutt AR, Kravitz BG, Paul G, Cobitz AR, Nino AJ, Fitzpatrick LA. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2013 Apr;98(4):1519-28. doi: 10.1210/jc.2012-4018. Epub 2013 Feb 28. PubMed 23450056 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2011, 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2008
First posted
May 19, 2008
Start
Apr 21, 2008
Primary completionActual
Sep 16, 2010
CompletionActual
Sep 16, 2010
Results first posted
Mar 7, 2011
Last update
Apr 18, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00679939
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 19, 2008
Start date
Apr 21, 2008
Primary completion
Sep 16, 2010
Completion
Sep 16, 2010
Results posted
Mar 7, 2011
Last update
Apr 18, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosiglitazone · Metformin

Start the discussion